Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects
NCT ID: NCT01873950
Last Updated: 2018-03-08
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1
Total Enrollment
22 participants
Study Classification
INTERVENTIONAL
Study Start Date
2013-05-31
Study Completion Date
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study seeks to compare 4 known QT prolonging drugs versus placebo to determine their effects on electrophysiological and other clinical parameters. The underlying purpose is to determine if depolarization and repolarization effects caused by drugs with differing ionic channel mechanisms can be distinguished from one another, and to gauge the sensitivity and specificity of novel signal analyses for detection of depolarization and repolarization changes. Secondarily, to evaluate the exposure response relationship and drug induced effects on the heart rate biomarker relationship.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Effects of Domperidone on Cardiac Repolarization in Healthy Volunteers
NCT01643889
Healthy
COMPLETED
PHASE1
A Study to Evaluate the Effect of MCI-186 at Therapeutic and Supra-Therapeutic Doses on the QT Interval(QT)/Corrected QT Interval(QTc) Interval in Healthy Subjects
NCT04029090
Healthy Adult Subjects
COMPLETED
PHASE1
Empiric Quinidine for Asymptomatic Brugada Syndrome
NCT00789165
Arrhythmia
WITHDRAWN
PHASE2/PHASE3
A Safety Evaluation of ECG Intervals and Blood Pressure in Normal Healthy Volunteers After Use of Nebivolol, Atenolol, Moxifloxacin, or Placebo
NCT00158093
Hypertension
COMPLETED
PHASE1
Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE)
NCT00000464
Arrhythmia
Cardiovascular Diseases
Heart Arrest
+3 more
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This will be a randomized, double blind, 5 way crossover research study in healthy male and female subjects, 18 to 35 years of age, to compare 4 known QT prolonging drugs versus placebo to determine their effects on electrophysiological and other clinical parameters. To maintain the study blind, subjects will be blindfolded during study drug administration. The cardiologists at the central ECG laboratory (Spaulding Clinical Research, LLC) will be blinded to treatment, time, and study day/subject identifiers.
Subjects who meet all of the following inclusion criteria will be eligible to participate in the study:
1. Subject signs an Institutional Review Board (IRB) approved written informed consent and privacy language as per national regulations (e.g., Health Insurance Portability and Accountability Act \[HIPAA\] authorization for sites in the United States) before any study related procedures are performed.
2. Subject is a healthy man or woman, 18 to 35 years of age, inclusive, who weighs at least 50 kg (110 pounds) and has a body mass index of 18 to 27 kg/m2, inclusive, at Screening.
3. Subject has normal medical history findings, clinical laboratory results, vital sign measurements, 12 lead ECG results, and physical examination findings at Screening or, if abnormal, the abnormality is not considered clinically significant (as determined and documented by the investigator or designee).
4. Female subjects must be at least 2 years postmenopausal, surgically sterile or practicing 2 highly effective methods of birth control (as determined by the investigator or designee; one of the methods must be a barrier technique), and not pregnant or lactating before enrollment in the study.
5. Male or female subjects must agree to practice 2 highly effective methods of birth control (as determined by the investigator or designee; one of the methods must be a barrier technique) from Screening until 30 days after the last dose of study drug.
6. Subject is highly likely (as determined by the investigator) to comply with the protocol-defined procedures and to complete the study.
Subjects who meet all of the following inclusion criteria will be eligible to participate in the study:
1. Subject signs an Institutional Review Board (IRB) approved written informed consent and privacy language as per national regulations (e.g., Health Insurance Portability and Accountability Act \[HIPAA\] authorization for sites in the United States) before any study related procedures are performed.
2. Subject is a healthy man or woman, 18 to 35 years of age, inclusive, who weighs at least 50 kg (110 pounds) and has a body mass index of 18 to 27 kg/m2, inclusive, at Screening.
3. Subject has normal medical history findings, clinical laboratory results, vital sign measurements, 12 lead ECG results, and physical examination findings at Screening or, if abnormal, the abnormality is not considered clinically significant (as determined and documented by the investigator or designee).
4. Female subjects must be at least 2 years postmenopausal, surgically sterile or practicing 2 highly effective methods of birth control (as determined by the investigator or designee; one of the methods must be a barrier technique), and not pregnant or lactating before enrollment in the study.
5. Male or female subjects must agree to practice 2 highly effective methods of birth control (as determined by the investigator or designee; one of the methods must be a barrier technique) from Screening until 30 days after the last dose of study drug.
6. Subject is highly likely (as determined by the investigator) to comply with the protocol-defined procedures and to complete the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Drug-induced Surface ECG Changes
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
CROSSOVER
Primary Study Purpose
TREATMENT
Blinding Strategy
DOUBLE
Participants
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ranolazine 1500mg
Ranolazine
Group Type
EXPERIMENTAL
Ranolazine
Intervention Type
DRUG
Dofetilide 500mcg
Dofetilide
Group Type
EXPERIMENTAL
Dofetilide
Intervention Type
DRUG
Verapamil HCl 120 mg
Verapamil
Group Type
EXPERIMENTAL
Verapamil
Intervention Type
DRUG
Quinidine sulfate 400mg
Quinidine sulfate
Group Type
EXPERIMENTAL
Quinidine sulfate
Intervention Type
DRUG
Placebo
Placebo
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
DRUG
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ranolazine
Intervention Type
DRUG
Dofetilide
Intervention Type
DRUG
Verapamil
Intervention Type
DRUG
Quinidine sulfate
Intervention Type
DRUG
Placebo
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Subject signs an IRB approved written informed consent and privacy language as per national regulations (e.g., Health Insurance Portability and Accountability Act \[HIPAA\] authorization for sites in the United States) before any study related procedures are performed.
2. Subject is a healthy man or woman, 18 to 35 years of age, inclusive, who weighs at least 50 kg (110 pounds) and has a body mass index of 18 to 27 kg/m2, inclusive, at Screening.
3. Subject has normal medical history findings, clinical laboratory results, vital sign measurements, 12 lead electrocardiogram (ECG) results, and physical examination findings at Screening or, if abnormal, the abnormality is not considered clinically significant (as determined and documented by the investigator or designee).
4. Female subjects must be at least 2 years postmenopausal, surgically sterile or practicing 2 highly effective methods of birth control (as determined by the investigator or designee; one of the methods must be a barrier technique), and not pregnant or lactating before enrollment in the study.
5. Male or female subjects must agree to practice 2 highly effective methods of birth control (as determined by the investigator or designee; one of the methods must be a barrier technique) from Screening until 30 days after the last dose of study drug.
6. Subject is highly likely (as determined by the investigator) to comply with the protocol defined procedures and to complete the study.
2. Subject is a healthy man or woman, 18 to 35 years of age, inclusive, who weighs at least 50 kg (110 pounds) and has a body mass index of 18 to 27 kg/m2, inclusive, at Screening.
3. Subject has normal medical history findings, clinical laboratory results, vital sign measurements, 12 lead electrocardiogram (ECG) results, and physical examination findings at Screening or, if abnormal, the abnormality is not considered clinically significant (as determined and documented by the investigator or designee).
4. Female subjects must be at least 2 years postmenopausal, surgically sterile or practicing 2 highly effective methods of birth control (as determined by the investigator or designee; one of the methods must be a barrier technique), and not pregnant or lactating before enrollment in the study.
5. Male or female subjects must agree to practice 2 highly effective methods of birth control (as determined by the investigator or designee; one of the methods must be a barrier technique) from Screening until 30 days after the last dose of study drug.
6. Subject is highly likely (as determined by the investigator) to comply with the protocol defined procedures and to complete the study.
Exclusion Criteria
1. Subject has a 12 lead safety ECG result at Screening or Check in of Period 1 with evidence of any of the following abnormalities:
* QTc using Fridericia correction (QTcF) \>450 milliseconds (ms) for men and \>470 ms for women
* PR interval \>220 ms
* QRS duration \>110 ms
* Second- or third-degree atrioventricular block
* Complete left or right bundle branch block or incomplete right bundle branch block
* Heart rate \<40 or \>90 beats per minute
* Pathological Q-waves (defined as Q wave \>40 ms)
* Ventricular pre-excitation
2. Subject has more than 12 to 20 ectopic beats during the 3 hour Holter ECG at Screening.
3. Subject has a history of unexplained syncope, structural heart disease, long QT syndrome, heart failure, myocardial infarction, angina, unexplained cardiac arrhythmia, torsades de pointes, ventricular tachycardia, or placement of a pacemaker or implantable defibrillator. Subjects will also be excluded if there is a family history of long QT syndrome (genetically proven or suggested by sudden death of a close relative due to cardiac causes at a young age) or Brugada syndrome.
4. Subject has a history or current evidence of any clinically significant (as determined by the investigator) cardiovascular, dermatologic, endocrine, gastrointestinal, hematologic, hepatic, immunologic, metabolic, neurologic, psychiatric, pulmonary, renal, urologic, and/or other major disease or malignancy (excluding nonmelanoma skin cancer). The investigator may allow exceptions to these criteria (e.g., stable mild joint disease \[that will not interfere with or influence the leg raises/exercises required by the protocol, in the opinion of the investigator\], cholecystectomy, childhood asthma) following discussion with the medical monitor.
5. Subject has a history of thoracic surgery.
6. Subject has any condition possibly affecting study drug absorption (e.g., gastrectomy, Crohn's disease, irritable bowel syndrome).
7. Subject has a skin condition likely to compromise ECG electrode placement.
8. Subject is a female with breast implants.
9. Subject's laboratory test results at Screening or Check in of Period 1 are outside the reference ranges provided by the clinical laboratory and considered clinically significant (as determined and documented by the investigator or designee).
10. Subject's laboratory test results at Screening or Check in of Period 1 indicate hypokalemia, hypocalcemia, or hypomagnesemia according to lower limits of the reference ranges provided by the clinical laboratory.
11. Subject's laboratory test results at Screening or Check in of Period 1 are \>2 × the upper limit of normal (ULN) for alanine aminotransferase or aspartate aminotransferase, \>1.5 × ULN for bilirubin, or \>1.5 × ULN for creatinine.
12. Subject has a positive test result at Screening for human immunodeficiency virus antibody, hepatitis C antibodies, or hepatitis B surface antigen.
13. Subject has a mean systolic blood pressure \<90 or \>140 mmHg or a mean diastolic blood pressure \<50 or \>90 mmHg at either Screening or Check in of Period 1. Blood pressure will be measured in triplicate after the subject has been resting in a supine position for a minimum of 5 minutes.
14. Subject has a known hypersensitivity to ranolazine, dofetilide, verapamil, or quinidine or related compounds.
15. Subject has consumed alcohol, xanthine containing products (e.g., tea, coffee, chocolate, cola), caffeine, grapefruit, or grapefruit juice within 48 hours before dosing or anticipates an inability to abstain from these products throughout the duration of the study.
16. Subject has used nicotine containing products (e.g., cigarettes, cigars, chewing tobacco, snuff) within 6 weeks before Screening (self reported).
17. Subject is unable to tolerate a controlled, quiet study conduct environment, including avoidance of music, television, movies, games, and activities that may cause excitement, emotional tension, or arousal during the prespecified time points (e.g., before and during ECG extraction windows).
18. Subject is unwilling to comply with study rules, including the study specific diet, attempting to void at specified times (e.g., before ECG extraction windows), remaining quiet, awake, undistracted, motionless, and supine during specified times, and avoiding vigorous exercise as directed.
19. Subject has a history of consuming more than 14 units of alcoholic beverages per week within 6 months before Screening, has a history of alcoholism or drug/chemical/substance abuse within 2 years before Screening (Note: 1 unit = 12 ounces of beer, 4 ounces of wine or 1 ounce of spirits/hard liquor), or has a positive test result for alcohol or drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, and opiates) at Screening or Check in of each period.
20. Subject has used any prescription or nonprescription drugs within 14 days or 5 half lives (whichever is longer), or complementary and alternative medicines within 28 days before the first dose of study drug (excluding oral contraceptives, hormone replacement therapy, aspirin, ibuprofen, and acetaminophen).
21. Subject is currently participating in another clinical study of an investigational drug or has been treated with any investigational drug within 30 days or 5 half lives (whichever is longer) of the compound.
22. Subject has had any significant blood loss, donated 1 unit (450 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days, or donated plasma within 7 days before Check in of Period 1.
23. Subject has any other condition that precludes his or her participation in the study (as determined by the investigator).
* QTc using Fridericia correction (QTcF) \>450 milliseconds (ms) for men and \>470 ms for women
* PR interval \>220 ms
* QRS duration \>110 ms
* Second- or third-degree atrioventricular block
* Complete left or right bundle branch block or incomplete right bundle branch block
* Heart rate \<40 or \>90 beats per minute
* Pathological Q-waves (defined as Q wave \>40 ms)
* Ventricular pre-excitation
2. Subject has more than 12 to 20 ectopic beats during the 3 hour Holter ECG at Screening.
3. Subject has a history of unexplained syncope, structural heart disease, long QT syndrome, heart failure, myocardial infarction, angina, unexplained cardiac arrhythmia, torsades de pointes, ventricular tachycardia, or placement of a pacemaker or implantable defibrillator. Subjects will also be excluded if there is a family history of long QT syndrome (genetically proven or suggested by sudden death of a close relative due to cardiac causes at a young age) or Brugada syndrome.
4. Subject has a history or current evidence of any clinically significant (as determined by the investigator) cardiovascular, dermatologic, endocrine, gastrointestinal, hematologic, hepatic, immunologic, metabolic, neurologic, psychiatric, pulmonary, renal, urologic, and/or other major disease or malignancy (excluding nonmelanoma skin cancer). The investigator may allow exceptions to these criteria (e.g., stable mild joint disease \[that will not interfere with or influence the leg raises/exercises required by the protocol, in the opinion of the investigator\], cholecystectomy, childhood asthma) following discussion with the medical monitor.
5. Subject has a history of thoracic surgery.
6. Subject has any condition possibly affecting study drug absorption (e.g., gastrectomy, Crohn's disease, irritable bowel syndrome).
7. Subject has a skin condition likely to compromise ECG electrode placement.
8. Subject is a female with breast implants.
9. Subject's laboratory test results at Screening or Check in of Period 1 are outside the reference ranges provided by the clinical laboratory and considered clinically significant (as determined and documented by the investigator or designee).
10. Subject's laboratory test results at Screening or Check in of Period 1 indicate hypokalemia, hypocalcemia, or hypomagnesemia according to lower limits of the reference ranges provided by the clinical laboratory.
11. Subject's laboratory test results at Screening or Check in of Period 1 are \>2 × the upper limit of normal (ULN) for alanine aminotransferase or aspartate aminotransferase, \>1.5 × ULN for bilirubin, or \>1.5 × ULN for creatinine.
12. Subject has a positive test result at Screening for human immunodeficiency virus antibody, hepatitis C antibodies, or hepatitis B surface antigen.
13. Subject has a mean systolic blood pressure \<90 or \>140 mmHg or a mean diastolic blood pressure \<50 or \>90 mmHg at either Screening or Check in of Period 1. Blood pressure will be measured in triplicate after the subject has been resting in a supine position for a minimum of 5 minutes.
14. Subject has a known hypersensitivity to ranolazine, dofetilide, verapamil, or quinidine or related compounds.
15. Subject has consumed alcohol, xanthine containing products (e.g., tea, coffee, chocolate, cola), caffeine, grapefruit, or grapefruit juice within 48 hours before dosing or anticipates an inability to abstain from these products throughout the duration of the study.
16. Subject has used nicotine containing products (e.g., cigarettes, cigars, chewing tobacco, snuff) within 6 weeks before Screening (self reported).
17. Subject is unable to tolerate a controlled, quiet study conduct environment, including avoidance of music, television, movies, games, and activities that may cause excitement, emotional tension, or arousal during the prespecified time points (e.g., before and during ECG extraction windows).
18. Subject is unwilling to comply with study rules, including the study specific diet, attempting to void at specified times (e.g., before ECG extraction windows), remaining quiet, awake, undistracted, motionless, and supine during specified times, and avoiding vigorous exercise as directed.
19. Subject has a history of consuming more than 14 units of alcoholic beverages per week within 6 months before Screening, has a history of alcoholism or drug/chemical/substance abuse within 2 years before Screening (Note: 1 unit = 12 ounces of beer, 4 ounces of wine or 1 ounce of spirits/hard liquor), or has a positive test result for alcohol or drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, and opiates) at Screening or Check in of each period.
20. Subject has used any prescription or nonprescription drugs within 14 days or 5 half lives (whichever is longer), or complementary and alternative medicines within 28 days before the first dose of study drug (excluding oral contraceptives, hormone replacement therapy, aspirin, ibuprofen, and acetaminophen).
21. Subject is currently participating in another clinical study of an investigational drug or has been treated with any investigational drug within 30 days or 5 half lives (whichever is longer) of the compound.
22. Subject has had any significant blood loss, donated 1 unit (450 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days, or donated plasma within 7 days before Check in of Period 1.
23. Subject has any other condition that precludes his or her participation in the study (as determined by the investigator).
Minimum Eligible Age
18 Years
Maximum Eligible Age
35 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Spaulding Clinical Research LLC
OTHER
Sponsor Role
collaborator
Food and Drug Administration (FDA)
FED
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Carlos Sanabria, MD
Role: PRINCIPAL_INVESTIGATOR
Spaulding Clinical Research LLC
References
Explore related publications, articles, or registry entries linked to this study.
Johannesen L, Vicente J, Mason JW, Sanabria C, Waite-Labott K, Hong M, Guo P, Lin J, Sorensen JS, Galeotti L, Florian J, Ugander M, Stockbridge N, Strauss DG. Differentiating drug-induced multichannel block on the electrocardiogram: randomized study of dofetilide, quinidine, ranolazine, and verapamil. Clin Pharmacol Ther. 2014 Nov;96(5):549-58. doi: 10.1038/clpt.2014.155. Epub 2014 Jul 23.
Reference Type
RESULT
Vicente J, Johannesen L, Mason JW, Crumb WJ, Pueyo E, Stockbridge N, Strauss DG. Comprehensive T wave morphology assessment in a randomized clinical study of dofetilide, quinidine, ranolazine, and verapamil. J Am Heart Assoc. 2015 Apr 13;4(4):e001615. doi: 10.1161/JAHA.114.001615.
Reference Type
RESULT
Vicente J, Johannesen L, Mason JW, Pueyo E, Stockbridge N, Strauss DG. Sex differences in drug-induced changes in ventricular repolarization. J Electrocardiol. 2015 Nov-Dec;48(6):1081-7. doi: 10.1016/j.jelectrocard.2015.08.004. Epub 2015 Aug 4.
Reference Type
RESULT
Strauss DG, Vicente J, Johannesen L, Blinova K, Mason JW, Weeke P, Behr ER, Roden DM, Woosley R, Kosova G, Rosenberg MA, Newton-Cheh C. Common Genetic Variant Risk Score Is Associated With Drug-Induced QT Prolongation and Torsade de Pointes Risk: A Pilot Study. Circulation. 2017 Apr 4;135(14):1300-1310. doi: 10.1161/CIRCULATIONAHA.116.023980. Epub 2017 Feb 17.
Reference Type
DERIVED
Vicente J, Johannesen L, Hosseini M, Mason JW, Sager PT, Pueyo E, Strauss DG. Electrocardiographic Biomarkers for Detection of Drug-Induced Late Sodium Current Block. PLoS One. 2016 Dec 30;11(12):e0163619. doi: 10.1371/journal.pone.0163619. eCollection 2016.
Reference Type
DERIVED
Johannesen L, Vicente J, Hosseini M, Strauss DG. Automated Algorithm for J-Tpeak and Tpeak-Tend Assessment of Drug-Induced Proarrhythmia Risk. PLoS One. 2016 Dec 30;11(12):e0166925. doi: 10.1371/journal.pone.0166925. eCollection 2016.
Reference Type
DERIVED
Study Documents
Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.
Document Type: ECG, PK and clinical information database
This publicly available database contains raw and annotated ECG signals, PK measures as well as clinical information of this study.
View DocumentOther Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SCR-002
Identifier Type: -
Identifier Source: secondary_id
13-011D
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Effect of Beta-blocker Therapy on QTc Response in Exercise and Recovery in Normal Subjects
NCT00588965
COMPLETED
NA
Efficacy and Safety of memanTine in the Treatment Of Frequently symPtomatic Atrial Premature Beats
NCT06501638
COMPLETED
PHASE2
Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart
NCT01798992
COMPLETED
PHASE4
Dobutamine on the Cardiac Conduction System
NCT04249258
COMPLETED
EARLY_PHASE1
Pharmacodynamic Effects, Safety and Tolerability of Cilobradine, Compared to Metoprolol Succinate and Placebo in Healthy Volunteers
NCT02264002
COMPLETED
PHASE1
Study to Evaluate the Effects of Domperidone on Cardiac Repolarization in Chinese Healthy Participants
NCT02816853
COMPLETED
PHASE1
Targeting Sympathetic Overactivity in Heart Failure Patients With Statins
NCT01097785
COMPLETED
NA
Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects
NCT04688632
COMPLETED
PHASE1
Exercise Improve Sympathetic Modulation in Chronic Heart Failure Patients
NCT02219451
COMPLETED
PHASE4
Clonidine and Left Ventricular Dysfunction
NCT00213902
WITHDRAWN
CIQTP Prolongation : Role and Mechanism in Sudden Cardiac Death
NCT03387072
COMPLETED
Arrhythmias, Microalbuminuria and Corticosteroids
NCT03453931
COMPLETED
Analysis of Atropine and Propranolol Induced Changes
NCT00251602
COMPLETED
PHASE1
Defining the Electrocardiographic Effect of Propofol on the Ajmaline Provocation Drug Challenge: A Prospective Trial
NCT04580992
UNKNOWN
Pulse Reduction On Beta-blocker and Ivabradine Therapy
NCT02973594
COMPLETED
PHASE4
The Influence of Heart Rate Reduction Upon Central Arterial Pressure in Younger and Older Healthy Individuals
NCT01029223
WITHDRAWN
PHASE4
Effect of Estetrol Monohydrate (E4) on QTc Interval
NCT04819906
COMPLETED
PHASE1
Multicenter Study of Antiarrhythmic Medications for Treatment of Infants With Supraventricular Tachycardia
NCT00390546
COMPLETED
PHASE3
Physiologic Effect of Topical Nitroglycerin on Microcirculation Capacity in Patients With Circulatory Shock.
NCT05102734
COMPLETED
Effect of BMS-914392 on Pharmacokinetics of Metoprolol
NCT01211821
COMPLETED
PHASE1
Iatrogenic Chronotropic Incompetence and Exercise Tolerance in Heart Failure
NCT02086422
UNKNOWN
NA
Autonomic Control of the Circulation and VDR
NCT03513770
RECRUITING
EARLY_PHASE1
Diltiazem in Jervell and Lange-Nielsen Syndrome
NCT06534671
COMPLETED
PHASE4
Randomized Clinical Trial Comparing Transradial Catheterization With or Without Spasmolytic Drugs
NCT02343276
COMPLETED
PHASE3
Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT).
NCT03464019
TERMINATED
PHASE3